Oxford BioMedicaLSE:OXB -0.16%68 Days Payable is 36.13 as of Dec. 2025, which is 28% below its 10-year median of 50.33. GuruFocus rates LSE:OXB with a GF Score™ of 68/100 and a GF Value™ of £5.38 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, Oxford BioMedica ranks worse than 73.97% on this metric.
The historical rank and industry rank for Oxford BioMedica's Days Payable or its related term are showing as below:
LSE:OXB'
s Days Payable Range Over the Past 10 Years
Min: 37.73 Med: 50.33 Max: 79.63
Current: 40.07
During the past 13 years, Oxford BioMedica's highest Days Payable was 79.63. The lowest was 37.73. And the median was 50.33.
LSE:OXB's Days Payable is ranked worse than 73.97% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs LSE:OXB: 40.07
Oxford BioMedica's Days Payable
declined
from Dec. 2024 (48.08) to Dec. 2025 (36.13).
It may suggest that Oxford BioMedicaaccelerated paying its suppliers.
Oxford BioMedica Days Payable Related Terms
Oxford BioMedica Days Payable Historical Data
* Premium members only.
The historical data trend for Oxford BioMedica's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OXB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Oxford BioMedica's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford BioMedica Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford BioMedica's Days Payable distribution charts can be found below:
* The bar in red indicates where Oxford BioMedica's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Oxford BioMedica's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford BioMedica (LSE:OXB) has a Days Payable of 36.13 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oxford BioMedica and its competitors. This is 28% below median its historical median of 50.33. Over the past decade, Oxford BioMedica's Days Payable has ranged from 37.73 to 79.63. According to the industry distribution chart, Oxford BioMedica ranks #520 out of 703 companies in the Biotechnology industry, placing it in the top 74%.
Is Oxford BioMedica's Days Payable too high?
Oxford BioMedica's current Days Payable of 36.13 is 28% below median its 10-year median of 50.33. Over the past 10 years, this metric has ranged from a low of 37.73 to a high of 79.63. The Biotechnology industry median Days Payable is 113.76. Oxford BioMedica's value of 36.13 is 68.2% below this industry median. Based on the distribution chart, Oxford BioMedica ranks #520 out of 703 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oxford BioMedica has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oxford BioMedica's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford BioMedica ranks #520 out of 703 companies for Days Payable. This places Oxford BioMedica in the lower half of its industry. The industry median Days Payable is 113.76. Oxford BioMedica's value of 36.13 is 68.2% below this benchmark. Historically, Oxford BioMedica's own Days Payable has ranged from 37.73 to 79.63 over the past decade. While the company's 10-year median is 50.33 vs. the industry median of 113.76, Oxford BioMedica has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford BioMedica's current Days Payable of 36.13 is 68.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Oxford BioMedica and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford BioMedica's current Days Payable is 36.13, which is 28% below median its own 10-year median of 50.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioMedica stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioMedica (LSE:OXB) is currently considered Modestly Overvalued. The stock's GF Value™ is £5.38, compared to a current price of £6.23 — trading 15.8% above its estimated fair value. The current Days Payable is 36.13, which is 28% below median its 10-year median of 50.33 and 68.2% below the Biotechnology industry median of 113.76. Oxford BioMedica's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Oxford BioMedica (LSE:OXB), the current Days Payable is 36.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford BioMedica (LSE:OXB) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford BioMedica stock appears to be overvalued.
The current stock price of £6.23 is trading 15.8% above its estimated GF Value™ of £5.38.
GuruFocus considers Oxford BioMedica to be Modestly Overvalued.
Key valuation signals for LSE:OXB:
Days Payable: 36.13 (28% below median its 10-year median of 50.33)
GF Value™: £5.38 vs. price of £6.23 (15.8% above fair value)
Industry Position: 68.2% below the Biotechnology median (#520 of 703)
No single metric tells the full story. See the LSE:OXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
68GF Score
Get the complete analysis for LSE:OXB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OXB has been successfully added to your 
